Want to see CRDF full AI Analyst Report?
Top Page
Cardiff Oncology
(NASDAQ:CRDF)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.00
▼(-1.96% Downside)
Action:Reiterated
Date:09/14/26
The score is held down primarily by very weak financial performance (large ongoing losses and substantial cash burn despite minimal revenue), implying continued dependence on financing. Technical indicators provide some near-term support (positive MACD; price above 20/50-day averages), but longer-term trends are still negative (below 100/200-day averages) and momentum looks stretched (high Stoch). Valuation is difficult to justify with negative earnings and no dividend, while corporate events modestly improve clarity and liquidity but introduce dilution considerations.
Positive Factors
Low leverage
Extremely low leverage reduces fixed financial obligations and preserves flexibility for a development-stage biotech. Cardiff can focus capital on advancing its oncology pipeline without substantial debt service, while retaining greater capacity to pursue future financing or strategic options.
Negative Factors
Persistent cash burn
Large negative operating and free cash flow show that research and development spending is consuming substantial cash rather than funding operations internally. Continued cash burn increases dependence on financing and can constrain Cardiff’s ability to sustain or expand clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Extremely low leverage reduces fixed financial obligations and preserves flexibility for a development-stage biotech. Cardiff can focus capital on advancing its oncology pipeline without substantial debt service, while retaining greater capacity to pursue future financing or strategic options.
Read all positive factors
Cardiff Oncology (CRDF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$83.24M
Dividend YieldN/A
Average Volume (3M)731.75K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-6.96%
EPS Growth32.77%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.60
Shares Outstanding77,795,250
10 Day Avg. Volume494,226
30 Day Avg. Volume731,750
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue107.98
Enterprise Value/Gross Profit107.98
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$7.50Price Target Upside635.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$266.67K
Cardiff Oncology Business Overview & Revenue Model
Company Description
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for trea...
How the Company Makes Money
Cardiff Oncology is a clinical-stage biotechnology company and, as such, its business model is primarily oriented around research and development rather than recurring product sales. Publicly available information indicates the company has histori...
Cardiff Oncology Earnings Call Summary
Earnings Call Date:Feb 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong initial clinical data, successful capital raising efforts, and a solid financial position. However, some dependency on future FDA meetings and the early stage of PFS data might pose challenges. Overall, the sentiment is optimistic with clear progress, yet some uncertainties remain.Positive Updates
Encouraging Initial Data from CRDF-004 Trial
The trial showed a 64% ORR for patients on the 30 mg dose of onvansertib, compared to a 33% ORR in the control arm, indicating a strong efficacy signal.
Negative Updates
Pending FDA Discussions
While progress has been made, key decisions regarding dose selection and trial design depend on future FDA meetings, which could impact timelines.
Read all updates
Q4-2024 Updates
Positive
Negative
Encouraging Initial Data from CRDF-004 Trial
The trial showed a 64% ORR for patients on the 30 mg dose of onvansertib, compared to a 33% ORR in the control arm, indicating a strong efficacy signal.
Read all positive updates
Company Guidance
During the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call, guidance was provided on several key metrics and future plans for the company. The company highlighted an initial data set from the CRDF-004 trial, which showed a 64% overall response rate (ORR) for patients on the 30 mg dose of onvansertib, compared to 33% in the control arm. The trial focuses on first-line RAS-mutated metastatic colorectal cancer (mCRC), and aims to complete enrollment of 90 evaluable patients in early 2025. The company plans to release additional clinical data in the first half of 2025. Financially, Cardiff Oncology reported $91.7 million in cash and short-term investments as of December 31, 2024, following a $40 million capital raise. The company projects that these resources will support operations into the first quarter of 2027, with a quarterly cash burn of $10.3 million in Q4 2024. Additionally, Cardiff Oncology strengthened its intellectual property portfolio with a new patent for onvansertib, expected to expire no earlier than 2043.Cardiff Oncology Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 508.00K | 593.00K | 683.00K | 488.00K | 386.00K | 359.00K |
| Gross Profit | 508.00K | 593.00K | 683.00K | 488.00K | 386.00K | 359.00K |
| EBITDA | -38.89M | -44.95M | -45.03M | -41.04M | -38.47M | -27.84M |
| Net Income | -40.05M | -45.85M | -45.43M | -41.44M | -38.70M | -28.29M |
Balance Sheet | ||||||
| Total Assets | 37.33M | 61.88M | 97.19M | 81.64M | 116.19M | 149.54M |
| Cash, Cash Equivalents and Short-Term Investments | 34.52M | 58.30M | 91.75M | 74.82M | 105.27M | 140.82M |
| Total Debt | 457.00K | 832.00K | 1.52M | 2.15M | 2.71M | 3.12M |
| Total Liabilities | 10.80M | 16.50M | 14.24M | 11.90M | 9.85M | 9.13M |
| Stockholders Equity | 26.53M | 45.39M | 82.95M | 69.74M | 106.34M | 140.42M |
Cash Flow | ||||||
| Free Cash Flow | -40.92M | -37.97M | -37.77M | -31.47M | -34.71M | -23.25M |
| Operating Cash Flow | -40.85M | -37.92M | -37.69M | -30.89M | -33.82M | -23.04M |
| Investing Cash Flow | 36.44M | 1.34M | 13.73M | 36.20M | 38.15M | -131.45M |
| Financing Cash Flow | 2.83M | 2.58M | 53.78M | 0.00 | 75.00K | 35.45M |
Cardiff Oncology Technical Analysis
Negative
1.02
Price Trends
1.08
Positive
1.21
Negative
1.61
Negative
Market Momentum
<0.01
Positive
42.57
Neutral
12.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRDF, the sentiment is Negative. The current price of 1.02 is below the 20-day moving average (MA) of 1.24, below the 50-day MA of 1.08, and below the 200-day MA of 1.61, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 42.57 is Neutral, neither overbought nor oversold. The STOCH value of 12.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRDF.
Cardiff Oncology Risk Analysis
Cardiff Oncology disclosed 64 risk factors in its most recent earnings report. Cardiff Oncology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cardiff Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $728.83M | -2.86 | -58.03% | ― | -86.62% | 14.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $83.24M | -1.82 | -103.08% | ― | -6.96% | 32.77% | |
49 Neutral | $241.30M | -1.43 | -215.23% | ― | 291.42% | 11.70% | |
48 Neutral | $160.59M | -2.45 | -67.67% | ― | -100.00% | 17.74% | |
45 Neutral | $76.25M | -2.47 | 1020.21% | ― | ― | 2.05% |
* Healthcare Sector Average
CRDF
Cardiff Oncology
1.09
-1.29
-54.20%
ONCY
Oncolytics Biotech
0.60
-0.69
-53.52%
AVTX
Avalo Therapeutics
13.58
-0.64
-4.50%
GLSI
Greenwich LifeSciences
15.39
3.95
34.53%
MOLN
Molecular Partners
3.81
-0.08
-2.06%
PYXS
Pyxis Oncology
2.01
-0.90
-30.93%
Cardiff Oncology Corporate Events
Business Operations and StrategyExecutive/Board ChangesLegal Proceedings
Cardiff Oncology Amends Onvansertib License, Resolves Litigation
Positive
Sep 14, 2026
On September 14, 2026, Cardiff Oncology and Nerviano Medical Sciences agreed to a confidential settlement resolving litigation over inventorship and performance issues tied to their 2017 license for onvansertib, Cardiff’s lead PLK1 inhibitor...
Business Operations and StrategyPrivate Placements and Financing
Cardiff Oncology completes $10 million financing transaction
Positive
Jul 17, 2026
On July 14, 2026, Cardiff Oncology entered into agreements with institutional investors, officers and directors to sell a total of roughly 9.3 million shares of common stock and an equal number of accompanying warrants in a registered direct offer...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.